<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Maat-Pharma on 生物经济</title><link>https://cn.bioecon.ru/companies/maat-pharma/</link><description>Recent content in Maat-Pharma on 生物经济</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Wed, 01 Jul 2026 23:36:33 +0700</lastBuildDate><atom:link href="https://cn.bioecon.ru/companies/maat-pharma/index.xml" rel="self" type="application/rss+xml"/><item><title>微生物组治疗药物（活体生物治疗产品）</title><link>https://cn.bioecon.ru/technology/microbiome-therapeutics-lbps/</link><pubDate>Wed, 01 Jul 2026 00:00:00 +0000</pubDate><guid>https://cn.bioecon.ru/technology/microbiome-therapeutics-lbps/</guid><description>活体生物治疗产品（LBP）——经 GMP 工艺生产的标准化微生物菌群药物，获批用于治疗复发性艰难梭菌感染、炎症性肠病及免疫肿瘤学支持。</description></item></channel></rss>